Published on 1 Jun 2016
Ewan
Phillips, chief executive of Oesophageal Doppler monitoring (ODM)
specialist Deltex Medical Group plc (LON:DEMG) says results the latest
study of its ODM devices in Spain are “stunning”.
Results of the first independent, randomised, multi-centre ODM trial, which Phillips says is the “gold standard in clinical trials”, were presented at a major international clinical conference in London on Wednesday.
The chief executive adds that the study was “an important trial”, as it reaffirmed the data from previous trials conducted over the last 20 years.
He also notes that “it brings our evidence base bang up to date and it is the biggest trial ever of Oesophageal Doppler during surgery.”
http://www.4-traders.com/DELTEX-MEDICAL-GROUP-PLC-4002474/
Spanish Multi-Centre ODM Trial Shows Significant Im..
Deltex-Medical-Group-Plc - #UnitedKingdom : #Investment #Risk Forecast flabby Nov 2015 : https://t.co/08x48Rs85T #Investment #Stocks
— Investment Analysis (@Investment_Risk) November 15, 2015
No comments:
Post a Comment